ES2062417T3 - Composiciones farmaceuticas de cimetidina. - Google Patents

Composiciones farmaceuticas de cimetidina.

Info

Publication number
ES2062417T3
ES2062417T3 ES90313123T ES90313123T ES2062417T3 ES 2062417 T3 ES2062417 T3 ES 2062417T3 ES 90313123 T ES90313123 T ES 90313123T ES 90313123 T ES90313123 T ES 90313123T ES 2062417 T3 ES2062417 T3 ES 2062417T3
Authority
ES
Spain
Prior art keywords
cimetidine
pharmaceutical compositions
release
eudragit
intestine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90313123T
Other languages
English (en)
Inventor
Jacky Mention
Rene Tarral
Graham Stanley Leonard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Laboratoires Pharmaceutiques
Original Assignee
SmithKline Beecham Laboratoires Pharmaceutiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Laboratoires Pharmaceutiques filed Critical SmithKline Beecham Laboratoires Pharmaceutiques
Application granted granted Critical
Publication of ES2062417T3 publication Critical patent/ES2062417T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

SE DESCRIBEN LAS FORMAS DE DOSIS ORALES RETARDADAS-SUELTAS QUE COMPRENDEN CIMETIDINA O UNA SAL DE LA MISMA Y OPCIONALMENTE UN AMORTIGUADOR CAPAZ DE AYUDAR EN LA DISOLUCION DE LA CIMETIDINA EN LOS INTESTINOS, RECUBIERTO CON UNA SUSTANCIA DE RETARDO-LIBERACION QUE COMPRENDE UN AGENTE DE REVESTIMIENTO TAL COMO EL EUDRAGIT ELEVADO R L 30 D.
ES90313123T 1989-12-05 1990-12-04 Composiciones farmaceuticas de cimetidina. Expired - Lifetime ES2062417T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8916056A FR2655266B1 (fr) 1989-12-05 1989-12-05 Compositions pharmaceutiques a base de cimetidine.

Publications (1)

Publication Number Publication Date
ES2062417T3 true ES2062417T3 (es) 1994-12-16

Family

ID=9388166

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90313123T Expired - Lifetime ES2062417T3 (es) 1989-12-05 1990-12-04 Composiciones farmaceuticas de cimetidina.

Country Status (15)

Country Link
US (1) US5229134A (es)
EP (1) EP0431877B1 (es)
JP (1) JPH04145016A (es)
KR (1) KR910011257A (es)
AT (1) ATE112961T1 (es)
AU (1) AU629071B2 (es)
CA (1) CA2031066A1 (es)
DE (1) DE69013473T2 (es)
DK (1) DK0431877T3 (es)
ES (1) ES2062417T3 (es)
FR (1) FR2655266B1 (es)
IE (1) IE904364A1 (es)
NZ (1) NZ236326A (es)
PT (1) PT96078A (es)
ZA (1) ZA909685B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA919510B (en) * 1990-12-05 1992-10-28 Smithkline Beecham Corp Pharmaceutical compositions
US6224911B1 (en) * 1993-03-16 2001-05-01 Syntex (U.S.A.) Llc Process for the preparation of enteric coated pharmaceutical dosage forms
FR2723586A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Nouvelles compositions contenant de la cimetidine et associations en derivant
TR199701092T1 (xx) * 1995-04-03 1998-01-21 Chugai Seiyaku Kabushiki Kaisha Et Al Sukralfat içeren farmakotik kompozisyonlar.
US5789014A (en) * 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US5768140A (en) * 1996-06-21 1998-06-16 Symbol Technologies, Inc. RF-interrogatable processing system
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
WO2000028988A1 (en) * 1998-11-17 2000-05-25 Nitromed, Inc. Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
SE0100200D0 (sv) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
MXPA04002980A (es) * 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosificacion que tienen un nucleo interior y coraza exterior con diferentes formas.
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
BR0206441A (pt) 2001-12-19 2003-12-30 Astrazeneca Ab Composição de revestimento de pelìcula, revestimento de pelìcula cobrindo um núcleo farmacêutico, formulação farmacêutica de liberação modificada, e, processos para preparar uma composição de revestimento de pelìcula, um revestimento de pelìcula e uma formulação
AU2002357366A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Multiple-pulse extended release formulations of clindamycin
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
PE20050335A1 (es) * 2003-08-07 2005-06-01 Sb Pharmco Inc Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion
WO2005123042A1 (en) * 2004-06-10 2005-12-29 Glatt Air Techniques, Inc. Controlled release pharmaceutical formulation
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006103702A2 (en) * 2005-04-01 2006-10-05 Mccullough Ricky W Enhanced bio-adherent polymeric compositions for coating mucosal and epidermal epithelium
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
FR2887455B1 (fr) * 2005-06-28 2007-08-10 Sanofi Aventis Sa Formulation a liberation prolongee de principes actifs de medicaments
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
EP2034970B1 (en) * 2006-06-01 2012-08-01 MSD Consumer Care, Inc. Sustained release pharmaceutical formulation comprising phenylephrine
TWI405567B (zh) * 2006-06-01 2013-08-21 Merck Sharp & Dohme 持續釋放脫羥腎上腺素之醫藥組合物
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
US8282956B2 (en) * 2006-06-13 2012-10-09 Nippon Shinyaku Co. Ltd. Coated tablet
RU2013106514A (ru) 2007-10-12 2015-03-10 Такеда Фармасьютикалз Норт Америка, Инк. Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи
US8268356B2 (en) * 2007-11-16 2012-09-18 Asahi Kasei Chemicals Corporation Aqueous film coating solution, film coated granule and tablet using the same
CA2738197C (en) 2008-09-24 2016-01-05 Evonik Roehm Gmbh Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol
BRPI0924427A2 (pt) * 2009-03-18 2016-01-26 Evonik Roehm Gmbh composição farmacêutica de liberação controlada, seu processo de preparação e uso da mesma
JP5309262B2 (ja) 2009-12-02 2013-10-09 アプタリス ファーマ リミテッド フェキソフェナジン・マイクロカプセル及びそれを含む組成物
WO2013098842A2 (en) * 2011-11-03 2013-07-04 Wincoat Colours And Coatings Private Limited Novel film coating composition
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN111991364B (zh) * 2020-09-03 2022-07-22 四川省百草生物药业有限公司 一种盐酸洛美利嗪渗透泵片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4976949A (en) * 1985-10-25 1990-12-11 The University Of Michigan Controlled release dosage form
SE461891B (sv) * 1986-11-19 1990-04-09 Roland Palm Medel foer utvaertes behandling av husdjur, foerfarande foer framstaellning av naemnda medel samt anvaendning daerav foer behandling av juver och spenar hos kor
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
JP2646251B2 (ja) * 1987-10-20 1997-08-27 富士写真フイルム株式会社 多層同時塗布方法及び装置
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations

Also Published As

Publication number Publication date
IE904364A1 (en) 1991-06-05
ZA909685B (en) 1992-07-29
US5229134A (en) 1993-07-20
JPH04145016A (ja) 1992-05-19
EP0431877A1 (en) 1991-06-12
CA2031066A1 (en) 1991-06-06
AU629071B2 (en) 1992-09-24
DK0431877T3 (da) 1995-04-03
PT96078A (pt) 1991-09-30
NZ236326A (en) 1993-05-26
DE69013473D1 (de) 1994-11-24
AU6770490A (en) 1991-06-27
FR2655266A1 (fr) 1991-06-07
EP0431877B1 (en) 1994-10-19
FR2655266B1 (fr) 1992-04-03
DE69013473T2 (de) 1995-03-16
ATE112961T1 (de) 1994-11-15
KR910011257A (ko) 1991-08-07

Similar Documents

Publication Publication Date Title
ES2062417T3 (es) Composiciones farmaceuticas de cimetidina.
ATE75142T1 (de) Dhp-manteltablette.
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
DE69104777D1 (de) Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen.
ATE151285T1 (de) Orale arzneimittel mit kolonspezifischer freisetzung
DE68909772T2 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
SE8804628D0 (sv) New compounds
FR2618331B1 (fr) Compositions pharmaceutiques utiles pour le traitement de l'uremie
IT9019112A1 (it) Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
DE68920896T2 (de) N2-(1-Carboxy-3-phenylpropyl)-L-lysinderivate und Verfahren für die Herstellung von Lysinopril mit Hilfe dieser Verbindung.
TR27833A (tr) Antelmintik'lerin uygulanmasina mahsus ''pour-on'' formülasyonu.
ITMI912225A1 (it) Derivati ammonio quaternari di (-) e (+)-3-(10 h-fenotiazin-10- ilmetil)-l-azabiciclo (2. 2. 2. )ottano e composizioni farmaceutiche che li contengono
FR2677250B1 (fr) Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique.
IT9021021A0 (it) Composizioni farmaceutiche per la somministrazione orale di irudina
FR2684299B1 (fr) Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique et de l'amiloride.
FR2541114B1 (fr) Compositions pharmaceutiques antifongiques utilisables par voie orale contenant de l'omoconazole
FR2702960B1 (fr) Leurre pour l'administration orale de médicaments vétérinaires.
RU93042104A (ru) Противокашлевая композиция, содержащая декстрометорфан, способ ее применения
FR2608597B1 (fr) Compositions pharmaceutiques contenant de l'acetylsalicylate de lysine
IT8820571A0 (it) Agente antiinfiammatorio per la terapia dell'ipertrofia prostatica, sua preparazione e relative composizioni farmaceutiche.
FI830192A0 (fi) Foerfarande foer framstaellning av penicillinderivat
IT8820301A0 (it) Procedimento per la preparazione dell'acido 5_aminosalicilico e composizioni farmaceutiche che lo contengono.
IT1142260B (it) L-alanina come agente farmaceutico impiegato per la cura di cerebropatie vascolari e relative formulazioni
FR2655344B1 (fr) Derives heterocycliques d'acylaminothiazoles, leur preparation et compositions pharmaceutiques en contenant.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 431877

Country of ref document: ES